The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials Total ...

Neoadjuvant therapy has transformed the management of locally advanced rectal cancer by delivering systemic and local treatments before surgery, with the dual aims of tumour downstaging and sphincter ...

In a multicentre study of patients with locally advanced rectal cancer, substantial variation existed in the choice of total neoadjuvant therapy (TNT), but efficacy was comparable across different ...

Neoadjuvant therapy with immunotherapy in pMMR/MSS rectal cancer shows high response rates and favorable surgical outcomes, with manageable safety profiles. Short-course chemoradiotherapy demonstrates ...

Immunotherapy wipes out some colorectal tumors without surgery, signaling a major shift toward less invasive treatment.

According to a meta-analysis of randomized clinical trials (RCTs), pathologic complete response (pCR) was not associated with overall or disease-free survival in patients with rectal cancer, ...

Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immuno-oncology. ICIs act on cancer cells by blocking the interaction between immune checkpoint proteins on immune cells and ...

One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment ...